- Home
- LANV vs VYGR Comparison
LANV vs VYGR Comparison
Compare LANV & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LANV
- VYGR
- Stock Information
- Founded
- LANV 2015
- VYGR 2013
- Country
- LANV China
- VYGR United States
- Employees
- LANV N/A
- VYGR N/A
- Industry
- LANV Blank Checks
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- LANV Finance
- VYGR Health Care
- Exchange
- LANV Nasdaq
- VYGR Nasdaq
- Market Cap
- LANV 220.6M
- VYGR 235.4M
- IPO Year
- LANV N/A
- VYGR 2015
- Fundamental
- Price
- LANV $2.04
- VYGR $4.22
- Analyst Decision
- LANV
- VYGR Strong Buy
- Analyst Count
- LANV 0
- VYGR 9
- Target Price
- LANV N/A
- VYGR $15.53
- AVG Volume (30 Days)
- LANV 59.6K
- VYGR 380.0K
- Earning Date
- LANV 03-04-2025
- VYGR 03-03-2025
- Dividend Yield
- LANV N/A
- VYGR N/A
- EPS Growth
- LANV N/A
- VYGR N/A
- EPS
- LANV N/A
- VYGR 0.47
- Revenue
- LANV $409,961,427.00
- VYGR $163,784,000.00
- Revenue This Year
- LANV N/A
- VYGR N/A
- Revenue Next Year
- LANV $10.45
- VYGR N/A
- P/E Ratio
- LANV N/A
- VYGR $9.05
- Revenue Growth
- LANV N/A
- VYGR 3.40
- 52 Week Low
- LANV $0.91
- VYGR $4.00
- 52 Week High
- LANV $3.78
- VYGR $10.66
- Technical
- Relative Strength Index (RSI)
- LANV 55.19
- VYGR 29.98
- Support Level
- LANV $1.70
- VYGR $4.20
- Resistance Level
- LANV $2.05
- VYGR $4.60
- Average True Range (ATR)
- LANV 0.21
- VYGR 0.31
- MACD
- LANV 0.01
- VYGR -0.08
- Stochastic Oscillator
- LANV 50.68
- VYGR 12.36
About LANV Lanvin Group Holdings Limited
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.